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Abstract 
Background: Protoilludene is a valuable sesquiterpene and serves as a precursor for several medicinal compounds 
and antimicrobial chemicals. It can be synthesized by heterologous expression of protoilludene synthase in Escheri-
chia coli with overexpression of mevalonate (MVA) or methylerythritol‑phosphate (MEP) pathway, and farnesyl diphos‑
phate (FPP) synthase. Here, we present E. coli as a cell factory for protoilludene production.
Results: Protoilludene was successfully produced in E. coli by overexpression of a hybrid exogenous MVA pathway, 
endogenous FPP synthase (IspA), and protoilludene synthase (OMP7) of Omphalotus olearius. For improving protoil‑
ludene production, the MVA pathway was engineered to increase synthesis of building blocks isopentenyl diphos‑
phate (IPP) and dimethylallyl diphosphate (DMAPP) by sequential order permutation of the lower MVA portion (MvL), 
the alteration of promoters and copy numbers for the upper MVA portion (MvU), and the coordination of both por‑
tions, resulting in an efficient entire MVA pathway. To reduce the accumulation of mevalonate observed in the culture 
broth due to lower efficiency of the MvL than the MvU, the MvL was further engineered by homolog substitution 
with the corresponding genes from Staphylococcus aureus. Finally, the highest protoilludene production of 1199 mg/L 
was obtained from recombinant E. coli harboring the optimized hybrid MVA pathway in a test tube culture.
Conclusions: This is the first report of microbial synthesis of protoilludene by using an engineered E. coli strain. The 
protoilludene production was increased by approx. Thousandfold from an initial titer of 1.14 mg/L. The strategies of 
both the sequential order permutation and homolog substitution could provide a new perspective of engineering 
MVA pathway, and be applied to optimization of other metabolic pathways.
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Background
Protoilludene derivatives, including illudins, marasmanes 
and melleolides, are known to exert antitumor and anti-
microbial activities [1–3]. For example, the most brilliant 
potential anticancer agent illudin S, which is first isolated 
from Omphalotus olearius mushroom, has been studied 
extensively owing to its cytotoxicity to various tumor 
cell types [4]. These biological properties and medicinal 
potential have attracted considerable attention since the 
late 1960s. Illudins, marasmanes and melleolides can be 
synthesized from protoilludene by different oxygena-
tion reactions. For example, P450 monooxygenases for 
the biosynthesis of illudin have been identified from O. 
olearius [5]. However, protoilludene is naturally pro-
duced in a small quantity and its purification from bio-
logical material suffers from low yields. Hence, metabolic 
engineering of microorganisms, such as Escherichia coli, 
is an alternative and attractive route for the production of 
protoilludene.
Protoilludene biosynthesis begins with the for-
mation of the universal precursors, isopen-
tenyl pyrophosphate (IPP) and dimethylallyl 
pyrophosphate (DMAPP), which can be generated 
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via the methylerythritol-phosphate (MEP) pathway 
and the mevalonate (MVA) pathway [6]. Isopentenyl 
pyrophosphate and dimethylallyl pyrophosphate are 
condensed to form farnesyl diphosphate (FPP) by FPP 
synthase. Linear FPP undergoes multiple electrophilic 
cyclizations and rearrangements to generate tricyclic 
protoilludene with an action of protoilludene synthase, 
which has been isolated from various species includ-
ing O. olearius, Armillaria gallica, and Stereum hirsu-
tum [7–9]. O. olearius protoilludene synthase (OMP7) 
exhibits a superior catalytic efficiency (Kcat/Km) of 
(13.0 ± 2.0) × 104 M−1 s−1 among those protoilludene 
synthases (Additional file 1: Table S1) [8].
The entire protoilludene synthesis pathway via 
the MVA pathway can be divided into three por-
tions, referred to as “MvU” composed of acetyl-CoA 
acetyltransferase/3-hydroxy-3-methylglutaryl-CoA 
reductase (MvaE) and 3-hydroxy-3-methylglutaryl-
CoA synthase (MvaS), “MvL” composed of mevalonate 
kinase (MvaK1), phosphomevalonate kinase (MvaK2), 
diphosphomevalonate decarboxylase (MvaD) and IPP 
isomerase (IDI), and “AO” composed of FPP synthase 
(IspA) and protoilludene synthase (OMP7) (Fig. 1). The 
MVA pathway has been widely engineered for produc-
tion of several sesquiterpenes in E. coli [6, 10–12]. In 
this study, MVA pathway was engineered for a balanced 
expression of MvU and MvL portions to increase pro-
toilludene production. The MvL portion was optimized 
by sequential permutation of its constituent genes in 
consideration of transcriptional polarity, a general ten-
dency of lower expression of the genes distant from 
promoter in a multi-cistronic operon [13]. In the opti-
mized MvL portion by the random sequential permuta-
tion, the constituent genes would be arranged in their 
activities from low to high activities in the operon. The 
expression of MvU portion was modulated by changes 
of promoters and copy-numbers to tune mevalonate 
production to its utilization by MvL portion. Optimal 
coordination of the MvUs and MvLs portions of the 
MVA pathway were finally able to increase protoil-
ludene production from 1.14 to 721  mg/L. As accu-
mulation of mevalonate intermediate was observed in 
the culture broth, MvL portion was further engineered 
by substituting its constituent genes with their homo-
logues from Staphylococcus aureus. By the homolog 
substitution, protoilludene production was increased 
from 721 to 1199 mg/L in a test tube culture. The suc-
cessful production of protoilludene from E. coli is 
shown in this work and the recombinant E. coli harbor-
ing the combinatorially engineered hybrid MVA path-
way can serve as a basic platform host for production 
of other valuable terpenoids. 
Results and discussion
Establishment of a protoilludene biosynthesis pathway 
in E. coli
Up to now, 6 protoilludene synthases from three species 
were identified (Additional file 1: Table S1) [7–9]. Among 
them, O. olearius protoilludene synthase (OMP7) exhib-
its the highest catalytic efficiency which is higher than its 
homologs OMP6 and Stehi1|73029 by 10 and 30 times, 
respectively. In order to synthesize protoilludene in E. 
coli, a codon-optimized OMP7 gene was assembled with 
E. coli FPP synthase gene (ispA) to construct plasmid 
pTAO (Fig.  2a). It was transformed into E. coli DH5α, 
resulting in the strain E. coli AO. This strain was then cul-
tivated at 30 °C for 48 h in 2YT medium containing 2 % 
(v/v) of glycerol with overlaying 1 mL decane. Gas chro-
matographic (GC) analysis showed a new peak which was 
identified as protoilludene by gas chromatograph–mass 
Fig. 1 Schematic diagram of protoilludene biosynthesis via meva‑
lonate (MVA) pathway. Protoilludene biosynthesis pathway is divided 
into three portions: MvU (acetyl‑CoA to mevalonate), MvL (meva‑
lonate to IPP and DMAPP) and AO (IPP and DMAPP to protoilludene). 
MvU portion is composed of MvaE (HMG‑CoA reductase/acetyl‑CoA 
acetyltransferase) and MvaS (HMG‑CoA synthase). MvL portion is 
comprised of MvaK1 (mevalonate kinase), MvaK2 (phosphomeva‑
lonate kinase), MvaD (diphosphomevalonate decarboxylase) and IDI 
(IPP isomerase). AO portion consists of IspA (FPP synthase) and OMP7 
(protoilludene synthase). Illudins, marasmanes and melleolides are 
protoilludene derivatives. Pathway intermediates for protoilludene 
synthesis are as follows: A‑CoA, acetyl‑CoA; AA‑CoA, acetoacetyl‑CoA; 
HMG‑CoA, hydroxymethylglutaryl‑CoA; MVAP, phosphomevalonate; 
MVAPP, diphosphomevalonate; IPP, isopentenyl diphosphate; DMAPP, 
dimethylallyl diphosphate; and FPP, farnesyl diphosphate. Solid and 
dashed arrows indicate the identified and unidentified reactions, 
respectively
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spectrometer (GC–MS), and corresponded to 1.14 mg/L 
of protoilludene. The tiny production could be ascribed 
to an insufficient supply of IPP and DMAPP from the 
native MEP pathway.
Thus, the protoilludene synthesis plasmid pTAO was 
co-transformed with plasmid pSNA [14], which encodes 
a hybrid exogenous MVA pathway for sufficient supply of 
IPP and DMAPP, into E. coli DH5α, resulting in the strain 
E. coli AO/NA. Gas chromatographic analysis showed 
a specific peak with retention time of 5.7  min, which 
was subsequently confirmed as protoilludene by GC–
MS (Fig. 2b). For 48 h of culture, the strain E. coli AO/
NA produced 517  mg/L of protoilludene with an unde-
sired accumulation of mevalonate as much as 571 mg/L 
(Fig. 2c), indicating the suboptimal performance of MVA 
pathway encoded by pSNA. It is thus required to rede-
sign the MVA pathway, especially the lower portion of 
the MVA pathway for protoilludene production.
Optimization of the MvL portion of the MVA pathway 
by sequential order permutation
Expression levels of genes in an operon are known to be 
affected by their position within the operon [13]. If a gene 
is located at the tail end of the operon, its expression 
level is generally lower. Thus, relative expression levels of 
multi-genes in an operon can be affected by the sequen-
tial order of genes in the operon. A specific metabolic 
pathway encoded by an operon can be optimized by posi-
tional modulation of the constituent genes in the operon. 
Such an approach has been successfully applied to opti-
mization of zeaxanthin synthetic pathway in Bacillus 
subtilis [15]. The MvL portion of pSNA is composed of 
four genes SnMvaK1, SnMvaK2 and SnMvaD from Strep-
tococcus pneumoniae, and IDI from E. coli [10]. Optimi-
zation of the MvL portion was performed by sequential 
order permutation of three genes SnMvaK1, SnMvaK2 
and SnMvaD. The four genes were assembled in a “Bio-
brick” [16] fashion to construct six sequential order per-
mutated lower MVA pathway plasmids (pSMvL1–6) based 
on pSTV28 vector (Fig. 3a). The strains E. coli AO/MvL1–
6 resulting from the co-transformation of pSMvL1–6 and 
pTAO were evaluated for protoilludene production with 
supplementation of 4  mM (592.6  mg/L) (R, S)-meva-
lonate (Fig. 3b). The protoilludene production varied with 
the sequential order permutation in the MvLs. The high-
est protoilludene production of 137  mg/L was obtained 
from E. coli AO/MvL2, whereas E. coli AO/MvL4–6 pro-
duced low titers of protoilludene below 25 mg/L. Around 
80 mg/L of protoilludene was produced from E. coli AO/
MvL1, 3. Residual amounts of mevalonate in the culture 
broth were measured at the end of the culture to observe 
the consumption by the strains harboring these sequen-
tial order permutated plasmids (Additional file  1: Fig. 
S2). As expected, the mevalonate consumption gener-
ally corresponded to the protoilludene production. The 
residual mevalonate concentrations in culture of E. coli 
AO/MvL4–6 were as high as 3 mM (438.5 mg/L), whereas 
the concentrations in E. coli AO/MvL1, 3 and AO/MvL2 
were as low as around 1.7 mM (248.5 mg/L) and 1.3 mM 
(190.0  mg/L), respectively. Therefore, the lower MVA 
pathway plasmid pSMvL2 is found to have an optimized 
gene order for the best performance of the MvL por-
tion, and its order of SnMvaK1-SnMvaD-SnMvaK2-IDI 
is interestingly consistent with arrangement of the native 
genes in S. pneumoniae (GenBank: AE007317.1).
Fig. 2 Establishment of a protoilludene biosynthesis pathway in E. 
coli a Expression construct of AO portion. AO operon, which is com‑
posed of FPP synthase ispA from E. coli and protoilludene synthase 
OMP7 from O. olearius, is cloned into pTrc99A vector and designated 
as pTAO. Ec, the gene from E. coli; Oo, the gene from O. olearius. b 
Identification of protoilludene product. The decane phase from two‑
phase culture of E. coli AO/NA strain was subjected to GC and GC–MS 
analysis. c Protoilludene production and mevalonate accumulation 
in culture of the strain E. coli AO/NA. The strain was grown at 30 °C 
in 4 mL of 2YT medium with 2 % (v/v) glycerol for 24 and 48 h, 
and overlaid with 1 mL of decane. The dark gray and light gray bars 
indicate protoilludene production and mevalonate accumulation, 
respectively
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Coordination of MvU and MvL portions of MVA pathway 
for protoilludene production
To optimize the synthesis of mevalonate, the MvU por-
tion of the MVA pathway was cloned into three plas-
mids with different copy numbers and promoters, 
pBBR1MCS-2 (6–8 copies and lac promoter), pSTV28 
(10–15 copies and lac promoter), and pTrc99A (20–30 
copies and trc promoter) [12], which were designated 
as pBMvUL (LOW), pSMvUM (MEDIUM) and pTMvUH 
(HIGH), respectively (Fig.  4a). The alternations of copy 
number and promoter led to the differentiation of meva-
lonate producing capacity in a range of 104–215  mg/L 
per OD600 at 48 h (Fig. 4b), although there was no signifi-
cant difference in cell growth among these three strains 
(Additional file 1: Fig. S3).
Both MvUs and MvLs were then expressed in all com-
binations in E. coli to find an optimal combination of 
the two portions for protoilludene production. As the 
MvUL plasmid (pBMvUL) is compatible with the lower 
MVA portion plasmids (pSMvL1–6) and the protoil-
ludene plasmid (pTAO), E. coli can be transformed with 
the three plasmids for the combination of MvUs and 
MvLs in protoilludene production. However, the MvUM 
plasmid (pSMvUM) is not compatible with pSMvL1–6 
derived from the same cloning vector (pSTV28) and 
MvUM and MvL1–6 are combined in pSMvL1–6-MvUM 
(Additional file 1: Fig. S4). The MvUH portion was cloned 
into pTAO plasmid, resulting in pTAO-MvUH, because 
the MvUH plasmid (pTMvUH) is not compatible with 
the same vector originated pTAO plasmid (Additional 
file  1: Fig. S4). Escherichia coli AO/H1–H6 strains har-
boring pTAO-MvUH and pSMvL1–6 produced a little 
amount of protoilludene (<35 mg/L; Fig. 4c), accompany-
ing with accumulation of a large amount of mevalonate 
(>1300 mg/L). It indicated the MvUH produced too much 
mevalonate beyond the capacity of MvLs and the meta-
bolic unbalance between MvUH and MvLs caused even 
a significant decrease of cell growth (Additional file  1: 
Table S2). In contrast, there was no significant accumu-
lation of mevalonate in the strains of E. coli AO/L1-L6 
(pTAO/pSMvL1–6/pBMvUL) and E. coli AO/M1–M6 
(pTAO/pSMvL1-6-MvUM), which suggested the lower 
capacity of the upper portions MvUL and MvUM than the 
lower portion MvLs (Fig. 4d). In contrast, strains E. coli 
AO/L1–L6 and E. coli AO/M1–M6 did not exhibit sig-
nificant mevalonate accumulation (Fig. 4d). However, the 
poor mevalonate supply from MvUL compared to MvUM 
seems to restrict the protoilludene production. The high-
est protoilludene production of 721 mg/L was observed 
in E. coli AO/M2, which represented a 1.4-fold increase 
to the production from E. coli AO/NA.
Homolog substitution of the lower MVA portion genes
Kinetic properties of homolog enzymes from differ-
ent organisms are generally distinct from each other. 
Homolog enzymes of the lower MVA portion have also 
different kinetic properties. For example, S. pneumoniae 
mevalonate kinase (SnMvaK1) is subject to allosteric 
regulation by diphosphomevalonate, whereas S. aureus 
mevalonate kinase (SaMvaK1) without the allosteric 
regulation is competitively inhibited by isoprenyl diphos-
phates (DMAPP, IPP and FPP) [17, 18]. A metabolic 
pathway of interest can be improved by substituting a 
problematic constituent enzyme with its homolog with a 
desirable property [14]. In order to further improve the 
mevalonate pathway, the genes of the lower MVA portion 
MvL2 in pSMvL2 were substituted with their homologs 
from S. aureus, resulting into a new set of pSMvL7–13 
plasmids (Fig. 5a). The effect of the lower MVA portions 
MvL7–13 on protoilludene production was investigated 
in combination with the upper MVA pathway portions 
MvUM and MvUH in the same manner used in Fig.  4c. 
The upper MVA portion MvUL was excluded in this study 
because it was suspected to produce insufficient amount 
Fig. 3 Optimization of the lower (MvL) portion of MVA pathway by 
sequential order permutation. a Expression constructs of the sequen‑
tial order permutated MvL portions. MvL operon, containing MvaK1, 
MvaK2 and MvaD from S. pneumoniae, and IDI from E. coli, is cloned 
into pSTV28 vector. Sn, the gene from S. pneumoniae; Ec, the gene 
from E. coli; Plac, lac promoter. b Effect of sequential order permu‑
tated MvLs on protoilludene production and cell growth. The strains 
were grown for 48 h at 30 °C in 4 mL of 2YT medium containing 2 % 
(v/v) glycerol and 4 mM mevalonate with overlay of 1 mL decane. The 
dark and light gray bars indicate protoilludene production and cell 
growth, respectively
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of mevalonate for high production of protoilludene. The 
plasmids pSMvL7–13-MvUM were constructed to combine 
the upper portion MvUM and the lower portions MvL7–
13(Additional file 1: Fig. S4). The combinations of MvUH 
and MvL7–13 were conducted by co-transformation of 
pTAO-MvUH and pSMvL7-13. Interestingly, the strains 
E. coli AO/M7 (pTAO/pSMvL7-MvUM) and E. coli AO/
H7 (pTAO-MvUH and pSMvL7), containing the lower 
MVA portion MvL7 with homolog substitution of SaM-
vaK1 only, produced the enhanced protoilludene pro-
duction of 1199 and 740 mg/L, respectively (Fig. 5b and 
Additional file 1: Table S3). Other homolog substitutions 
failed to improve production of protoilludene (Fig.  5b). 
As the homolog substitution of SaMvaK1 with no allos-
teric inhibition by diphosphomevalonate is effective for 
protoilludene production, it is suspected the accumula-
tion of diphosphomevalonate in the strain E. coli AO/
M2 harboring the lower MVA portion MvL2 due to some 
bottleneck in the conversion of diphosphomevalonate to 
IPP by diphosphomevalonate decarboxylase.
Conclusions
It is demonstrated the feasibility of producing protoil-
ludene in engineered E. coli. Heterologous expression 
of the MVA pathway encoded by pSNA enabled the 
strain E. coli AO/NA to produce 517  mg/L of protoil-
ludene, but mevalonate was accumulated in a signifi-
cant amount as 571 mg/L due to the unbalanced upper 
and lower portions of the MVA pathway. To create a 
balanced efficient MVA pathway, we sequentially per-
muted the order of genes in the lower portion of the 
MVA pathway (MvL) and coordinated their expression 
with the upper portion of the MVA pathway (MvU) by 
alternations of copy-number and promoter of plasmids. 
Through this approach, 721 mg/L of protoilludene was 
produced with reduced accumulation of mevalonate 
in the strain E. coli AO/M2. The substitution of meva-
lonate kinase from S. pneumoniae with the homolog 
from S. aureus further increased protoilludene pro-
duction to 1199  mg/L. These results suggest that the 
optimized MVA pathway is efficient to supply IPP and 
Fig. 4 Coordination of the lower (MvL) and upper (MvU) portions of MVA pathway for protoilludene production. a Expression constructs of the 
MvU portions with alternations of promoter and copy‑number. MvU operon consists of MvaE and MvaS from E. faecalis. The two genes are cloned 
into pBBR1MCS‑2, pSTV28 and pTrc99A vectors, which are designated as pBMvUL, pSMvUM and pTMvUH, respectively. Ef, the gene from E. faecalis; 
Plac and Ptrc, lac promoter and trc promoter, respectively. Rectangles show replication origin of each plasmid. b Mevalonate production capacity 
of recombinant E. coli harboring each of pBMvUL, pSMvUM and pTMvUH. The strains were cultured in 2YT medium at 30 °C for 48 h. c and d Effect 
of combinations of MvUL,M,H and MvL1–6 on protoilludene production and mevalonate accumulation. The culture were carried out in 4 mL of 2YT 
medium containing 2 % (v/v) glycerol with overlay of 1 mL decane at 30 °C for 48 h
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DMAPP for protoilludene production and also can 
serve as a platform IPP/DMAPP synthesis pathway for 
production of other valuable terpenes.
Methods
Bacterial strains and growth conditions
Escherichia coli DH5α were grown in 2YT medium 
(16  g tryptone, 10  g yeast extract, and 5  g sodium 
chloride per 1L) at 37  °C for plasmid construction, 
and at 30  °C for protoilludene production. The seed 
culture grown overnight at 37  °C was inoculated with 
an optical density at 600  nm (OD600) of 0.1 into 2YT 
medium containing 2 % (v/v) glycerol. Escherichia coli 
strains   (Table  1) harboring the lower portion of the 
MVA pathway were cultured with addition of 4  mM 
mevalonate. Ampicillin (100  μg/mL), chlorampheni-
col (50  μg/mL), kanamycin (50  μg/mL) and 0.2  mM 
IPTG were added as required. To harvest protoilludene 
produced during culture, 1  mL of decane was initially 
overlaid on 4  mL of culture broth. Cell growth was 
determined by measuring the OD600. All experiments 
were carried out in duplicate.
Construction of plasmids
Basic molecular biology procedures, including restric-
tion enzyme digestion and bacterial transformation, were 
carried out as described in the literature [19]. DNA frag-
ments were amplified by PCR using Pfu DNA polymerase 
(SolGent, Daejeon, Korea) according to the manufactur-
er’s instructions. BglBricks assembly [16] was applied for 
Fig. 5 Optimization of MVA pathway by homolog substitution for the lower portion genes. a Expression constructs of the homolog substituted 
MvL portions. The homolog genes are from S. aureus and represented with prefixion of “Sa” to the gene name. b and c Effect of combinations of 
MvUM,H and MvL7–13 on protoilludene production and mevalonate accumulation. The culture were carried out in 4 mL of 2YT medium containing 
2 % (v/v) glycerol with overlay of 1 mL decane at 30 °C for 48 h
Table 1 Strains used in this study
This table is a brief description of strains used in this study. For more detailed 
information, refer to Additional file 1: Table S4
Names Descriptions Sources
E. coli AO E. coli DH5α harboring pTAO This study
E. coli AO/NA E. coli DH5α harboring pTAO and pSNA This study
E. coli AO/MvL1–6 E. coli DH5α harboring pTAO and 
pSMvL1–6
This study
E. coli AO/L1–L6 E. coli DH5α harboring pTAO, pSMvL1–6 
and pBMvUL
This study
E. coli AO/M1–M13 E. coli DH5α harboring pTAO and 
pSMvL1–13‑MvUM
This study
E. coli AO/H1–H13 E. coli DH5α harboring pTAOMvUH and 
pSMvL1–13
This study
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construction of various plasmids. The schematic diagram 
of the constructs is shown in figures and the detailed 
construction process was depicted in Additional file  1. 
All plasmids and primers used in this study are described 
in Additional file 1: Table S4.
Identification and quantification of protoilludene
The decane phase of the two-phase culture was collected 
and centrifuged for 10 min at 12,000 rpm to remove cell 
debris, and subsequently subjected to gas chromatogra-
phy (GC) and gas chromatography-mass spectrometry 
(GC–MS). The production of protoilludene was quanti-
fied using an Agilent Technologies 7890A gas chromato-
graph equipped with a flame ionization detector (FID). 
One μL of sample was injected at a split ratio of 1:10, and 
separated on a 19091  N-133 HP-INNOWAX column 
(length, 30  m; internal diameter, 0.25  mm; film thick-
ness, 250 μm). The oven temperature was initially held at 
80 °C for 1 min and was increased at a rate of 10 °C/min 
to 250 °C, where it was held for 1 min. Nitrogen was used 
as the carrier gas with an inlet pressure of 39  psi. The 
detector temperature was maintained at 260 °C. GC–MS 
analysis was run on a GCMS-2010 ultra mass spectrome-
ter (Shimadzu, Tokyo, Japan). Purified protoilludene was 
used as the standard compound to construct the stand-
ard curve (R2 > 0.99) for the estimation of protoilludene 
production (Additional file 1: Fig. S1).
Quantification of mevalonate
Mevalonate concentration was determined by GC analy-
sis. Culture filtrate was adjusted to pH 2 with 3 M HCl, 
incubated at 45  °C for 1  h, saturated with anhydrous 
Na2SO4, and extracted with ethyl acetate. The resulting 
samples were analyzed for mevalonate concentration 
using an Agilent Technologies 7890A gas chromatograph. 
The analytical temperature of the GC was controlled at 
an initial temperature of 180 °C for 1 min, then ramped 
to 200 °C gradually at 2.5 °C/min and held for 2 min. The 
detector temperature was maintained at 260 °C.
Additional file
Additional file 1: Construction of plasmids. Table S1. Comparison of 
protoilludene synthases reported in literatures. Table S2. Cell growth 
of recombinant E. coli harboring MVA pathway engineered in a way of 
various combinations of MvUL,M,H and MvL1–6. Table S3. Cell growth of 
recombinant E. coli harboring MVA pathway engineered with combina‑
tions of MvUM,H and MvL2,7–13. Table S4. Strains, plasmids and primers 
used in this study. Figure S1. GC‑FID standard curve of protoilludene. 
Figure S2. Residual mevalonate in culture of the strains E. coli AO/MvL1‑6 
with exogenous addition of mevalonate. Figure S3. Cell growth of E. coli 
strains harboring pBMvUL, pSMvUM and pTMvUH. Figure S4. Schematic 
diagram of pSMvL1–13‑MvUM and pTAOMvUH.
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